Pathological complete response in a POLE-mutated non-small cell lung cancer patient treated with perioperative chemo-immunotherapy: a case report and review of the literature

Abstract

Immune checkpoint inhibitor (ICI)-based immunotherapy has emerged as an effective strategy for stage III non-small cell lung cancer (NSCLC). However, predictive biomarkers of response remain limited. DNA polymerase epsilon (POLE) mutations, although rare in NSCLC, are associated with an increased tumor mutational burden and enhanced neoantigen presentation, both of which may promote immune sensitivity. A 52-year-old woman was diagnosed with stage IIIA NSCLC. Tumor programmed death-ligand 1 (PD-L1) expression was negative. Molecular profiling revealed a somatic POLE mutation (NM_006231.4 (POLE): c.1270C>G (p.Leu424Val)), without additional tumor alterations. A perioperative chemo-immunotherapy approach was implemented. After three cycles of neoadjuvant carboplatin, pemetrexed, and pembrolizumab, computed tomography (CT) scan revealed a significant response. Then, the patient underwent to curative-intent surgery. Histopathological examination demonstrated a pathological complete response (pCR). Adjuvant pembrolizumab (thirteen cycles) was administered without relevant toxicities. At 18-month follow-up, the patient remained disease-free with good performance status. In conclusion, we report the case of pCR in a POLE-mutated NSCLC patient treated with perioperative chemo-immunotherapy. Incorporating a POLE evaluation could improve the integrated decision-making process for patients with NSCLC in the perioperative setting. Prospective studies are warranted to validate this observation.

Keywords

biomarker / ICI / NSCLC / pCR / perioperative / POLE

References

[1] Siegel RL , Miller KD , Jemal A . Cancer statistics, 2020. CA Cancer J Clin 2020; 70(1): 7–30

[2] Aupérin A , Le Péchoux C , Rolland E , Curran WJ , Furuse K , Fournel P , Belderbos J , Clamon G , Ulutin HC , Paulus R , Yamanaka T , Bozonnat MC , Uitterhoeve A , Wang X , Stewart L , Arriagada R , Burdett S , Pignon JP . Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non–small-cell lung cancer. J Clin Oncol 2010; 28(13): 2181–2190

[3] NSCLC Meta-analysis Collaborative Group . Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet 2014; 383(9928): 1561–1571

[4] Lieber A , Makai A , Orosz Z , Kardos T , Isaac SJ , Tornyi I , Bittner N . The role of immunotherapy in early-stage and metastatic NSCLC. Pathol Oncol Res 2024; 30: 1611713

[5] Antonia SJ , Villegas A , Daniel D , Vicente D , Murakami S , Hui R , Yokoi T , Chiappori A , Lee KH , de Wit M , Cho BC , Bourhaba M , Quantin X , Tokito T , Mekhail T , Planchard D , Kim YC , Karapetis CS , Hiret S , Ostoros G , Kubota K , Gray JE , Paz-Ares L , de Castro Carpeño J , Wadsworth C , Melillo G , Jiang H , Huang Y , Dennis PA , Özgüroğlu M . Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med 2017; 377(20): 1919–1929

[6] Banna GL , Hassan MA , Signori A , Giunta EF , Maniam A , Anpalakhan S , Acharige S , Ghose A , Addeo A . Neoadjuvant chemo-immunotherapy for early-stage non-small cell lung cancer: a systematic review and meta-analysis. JAMA Netw Open 2024; 7(4): e246837

[7] de Marinis F , Ardizzoni A , Attili I , Bonanno L , Bria E , Cortinovis DL , Margaritora S , Mazzoni F , Mercadante E , Morabito A , Petrella F , Rea F , Salvi R , Solli P , Spaggiari L , Voltolini L , Gridelli C . Perioperative chemo-immunotherapy in non-oncogene-addicted resectable non-small cell lung cancer (NSCLC): Italian expert panel meeting. Curr Oncol 2025; 32(2): 110

[8] Waser NA , Quintana M , Schweikert B , Chaft JE , Berry L , Adam A , Vo L , Penrod JR , Fiore J , Berry DA , Goring S . Pathological response in resectable non-small cell lung cancer: a systematic literature review and meta-analysis. JNCI Cancer Spectr 2024; 8(3): pkae021

[9] Mino-Kenudson M , Schalper K , Cooper W , Dacic S , Hirsch FR , Jain D , Lopez-Rios F , Tsao MS , Yatabe Y , Beasley MB , Yu H , Sholl LM , Brambilla E , Chou TY , Connolly C , Wistuba I , Kerr KM , Lantuejoul S . Predictive biomarkers for immunotherapy in lung cancer: perspective from the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol 2022; 17(12): 1335–1354

[10] Liguori L , Salomone F , Viggiano A , Sabbatino F , Pepe S , Formisano L , Bianco R , Servetto A . KRAS mutations in advanced non-small cell lung cancer: from biology to novel therapeutic strategies. Crit Rev Oncol Hematol 2025; 205: 104554

[11] Tsuboi M , Herbst RS , John T , Kato T , Majem M , Grohé C , Wang J , Goldman JW , Lu S , Su WC , de Marinis F , Shepherd FA , Lee KH , Le NT , Dechaphunkul A , Kowalski D , Poole L , Bolanos A , Rukazenkov Y , Wu YL . Overall survival with osimertinib in resected EGFR-mutated NSCLC. N Engl J Med 2023; 389(2): 137–147

[12] Wu YL , Dziadziuszko R , Ahn JS , Barlesi F , Nishio M , Lee DH , Lee JS , Zhong W , Horinouchi H , Mao W , Hochmair M , de Marinis F , Migliorino MR , Bondarenko I , Lu S , Wang Q , Ochi Lohmann T , Xu T , Cardona A , Ruf T , Noe J , Solomon BJ . Alectinib in resected ALK-positive non-small-cell lung cancer. N Engl J Med 2024; 390(14): 1265–1276

[13] Lu S , Kato T , Dong X , Ahn MJ , Quang LV , Soparattanapaisarn N , Inoue T , Wang CL , Huang M , Yang JCH , Cobo M , Özgüroğlu M , Casarini I , Khiem DV , Sriuranpong V , Cronemberger E , Takahashi T , Runglodvatana Y , Chen M , Huang X , Grainger E , Ghiorghiu D , van der Gronde T , Ramalingam SS . Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. N Engl J Med 2024; 391(7): 585–597

[14] Garmezy B , Gheeya J , Lin HY , Huang Y , Kim T , Jiang X , Thein KZ , Pilié PG , Zeineddine F , Wang W , Shaw KR , Rodon J , Shen JP , Yuan Y , Meric-Bernstam F , Chen K , Yap TA . Clinical and molecular characterization of POLE mutations as predictive biomarkers of response to immune checkpoint inhibitors in advanced cancers. JCO Precis Oncol 2022; 6(6): e2100267

[15] Henninger EE , Pursell ZF . DNA polymerase ε and its roles in genome stability. IUBMB Life 2014; 66(5): 339–351

[16] Kim JY , Kronbichler A , Eisenhut M , Hong SH , van der Vliet HJ , Kang J , Shin JI , Gamerith G . Tumor mutational burden and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. Cancers (Basel) 2019; 11(11): 1798

[17] Verma S , Breadner D , Mittal A , Palma DA , Nayak R , Raphael J , Vincent M . An updated review of management of resectable stage III NSCLC in the era of neoadjuvant immunotherapy. Cancers (Basel) 2024; 16(7): 1302

[18] Provencio M , Nadal E , González-Larriba JL , Martínez-Martí A , Bernabé R , Bosch-Barrera J , Casal-Rubio J , Calvo V , Insa A , Ponce S , Reguart N , de Castro J , Mosquera J , Cobo M , Aguilar A , López Vivanco G , Camps C , López-Castro R , Morán T , Barneto I , Rodríguez-Abreu D , Serna-Blasco R , Benítez R , Aguado de la Rosa C , Palmero R , Hernando-Trancho F , Martín-López J , Cruz-Bermúdez A , Massuti B , Romero A . Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer. N Engl J Med 2023; 389(6): 504–513

[19] Forde PM , Spicer J , Lu S , Provencio M , Mitsudomi T , Awad MM , Felip E , Broderick SR , Brahmer JR , Swanson SJ , Kerr K , Wang C , Ciuleanu TE , Saylors GB , Tanaka F , Ito H , Chen KN , Liberman M , Vokes EE , Taube JM , Dorange C , Cai J , Fiore J , Jarkowski A , Balli D , Sausen M , Pandya D , Calvet CY , Girard N . Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 2022; 386(21): 1973–1985

[20] Lei J , Zhao J , Gong L , Ni Y , Zhou Y , Tian F , Liu H , Gu Z , Huang L , Lu Q , Wang X , Sun J , Yang E , Wang T , Zhong D , Wang J , Zhao Z , Liu Z , Wang C , Wang X , Lei G , Yan X , Jiang T . Neoadjuvant camrelizumab plus platinum-based chemotherapy vs chemotherapy alone for Chinese patients with resectable stage IIIA or IIIB (T3N2) non-small cell lung cancer: the TD-FOREKNOW randomized clinical trial. JAMA Oncol 2023; 9(10): 1348–1355

[21] König D , Savic Prince S , Rothschild SI . Targeted therapy in advanced and metastatic non-small cell lung cancer. an update on treatment of the most important actionable oncogenic driver alterations. Cancers (Basel) 2021; 13(4): 804

[22] Palles C , Cazier JB , Howarth KM , Domingo E , Jones AM , Broderick P , Kemp Z , Spain SL , Guarino E , Salguero I , Sherborne A , Chubb D , Carvajal-Carmona LG , Ma Y , Kaur K , Dobbins S , Barclay E , Gorman M , Martin L , Kovac MB , Humphray S , Lucassen A , Holmes CC , Bentley D , Donnelly P , Taylor J , Petridis C , Roylance R , Sawyer EJ , Kerr DJ , Clark S , Grimes J , Kearsey SE , Thomas HJW , McVean G , Houlston RS , Tomlinson I . Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet 2013; 45(2): 136–144

[23] Shinbrot E , Henninger EE , Weinhold N , Covington KR , Göksenin AY , Schultz N , Chao H , Doddapaneni H , Muzny DM , Gibbs RA , Sander C , Pursell ZF , Wheeler DA . Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication. Genome Res 2014; 24(11): 1740–1750

[24] Zheng S , Cao Y , Randall J , Yu H , Thomas TO . Integrating POLE/POLD1 mutated for immunotherapy treatment planning of advanced stage non-small cell lung cancer. Thorac Cancer 2023; 14(23): 2269–2274

[25] Ma X , Dong L , Liu X , Ou K , Yang L . POLE/POLD1 mutation and tumor immunotherapy. J Exp Clin Cancer Res 2022; 41(1): 216

[26] Liu L , Ruiz J , O’Neill SS , Grant SC , Petty WJ , Yang M , Chen K , Topaloglu U , Pasche B , Zhang W . Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1. Mol Cancer 2018; 17(1): 81

[27] Song Z , Cheng G , Xu C , Wang W , Shao Y , Zhang Y . Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer. Lung Cancer 2018; 118: 57–61

[28] Fu Y , Zheng Y , Wang PP , Chen YY , Ding ZY . Immunotherapy for a POLE mutation advanced non-small-cell lung cancer patient. Front Pharmacol 2022; 13: 817265

[29] Rousseau B , Bieche I , Pasmant E , Hamzaoui N , Leulliot N , Michon L , de Reynies A , Attignon V , Foote MB , Masliah-Planchon J , Svrcek M , Cohen R , Simmet V , Augereau P , Malka D , Hollebecque A , Pouessel D , Gomez-Roca C , Guimbaud R , Bruyas A , Guillet M , Grob JJ , Duluc M , Cousin S , de la Fouchardiere C , Flechon A , Rolland F , Hiret S , Saada-Bouzid E , Bouche O , Andre T , Pannier D , El Hajbi F , Oudard S , Tournigand C , Soria JC , Champiat S , Gerber DG , Stephens D , Lamendola-Essel MF , Maron SB , Diplas BH , Argiles G , Krishnan AR , Tabone-Eglinger S , Ferrari A , Segal NH , Cercek A , Hoog-Labouret N , Legrand F , Simon C , Lamrani-Ghaouti A , Diaz LA Jr , Saintigny P , Chevret S , Marabelle A . PD-1 blockade in solid tumors with defects in polymerase epsilon. Cancer Discov 2022; 12(6): 1435–1448

[30] Wang F , Zhao Q , Wang YN , Jin Y , He MM , Liu ZX , Xu RH . Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types. JAMA Oncol 2019; 5(10): 1504–1506

[31] Lara MS , Riess JW , Kaleka G , Borowsky A , McPherson JD , Godoy LA , Grego L , Lara PN Jr , Mitsiades N . POLE mutation associated with microsatellite instability and high tumor mutational burden confers exquisite sensitivity to immune checkpoint inhibitor therapy in non-small cell lung cancer: a case report and genomic database analysis. Clin Lung Cancer 2025; 26(3): e207–e213

RIGHTS & PERMISSIONS

Higher Education Press